For bladder cancer patients with micrometastatic disease, the standard cystectomy requires a significant delay for the operation and recovery. This window may allow unseen metastases to progress, suggesting that upfront, effective systemic therapy is more critical for survival than immediate major surgery.

During the consensus meeting, patient advocates successfully argued for a highly robust definition of "event-free survival." The final definition counts not just cancer recurrence, but also the need for any additional standard-of-care treatment—including intravesical therapy—as an "event," reflecting the patient's perspective on what constitutes a successful outcome.

Despite strong data favoring pre-surgical systemic therapy, a surgeon argues that many patients will continue to undergo surgery first. This is due to real-world factors like surgeons being the point of diagnosis, urgent symptoms requiring rapid intervention, and patient preferences to have the tumor removed immediately.

While new FDA-approved intravesical treatments like nadofaragene firadenovec and TAR-200 demonstrate high complete response rates initially, their effectiveness consistently diminishes over time. This highlights the ongoing challenge of achieving durable, long-term bladder preservation.

Historically, bladder-sparing options were primarily for patients unfit for radical cystectomy. Now, with advances in surgical techniques and perioperative care, fewer patients are deemed truly ineligible for surgery. This shift means new bladder-sparing strategies are being developed for a much broader patient population.

The chemoradiation control arm in SUNRISE 2 performed so well (e.g., 95% 1-year overall survival) that it challenges the long-held belief that surgery is unequivocally superior. This result, alongside other recent studies, suggests chemoradiation should be considered a potent standard-of-care contender for bladder preservation in appropriately selected patients.

Expert consensus shows a major paradigm shift: perioperative systemic therapy (like EV-Pembro, scoring 2.9) is the undisputed standard for muscle-invasive bladder cancer. Approaches starting with cystectomy alone now score below 1.8, formally branding them as inferior options.

The success of new treatments like immunotherapy and ADCs leads to more patients achieving a deep response. This high efficacy makes patients question the necessity of a radical cystectomy, a life-altering surgery, creating an urgent need for data-driven, bladder-sparing protocols.

With pathologic complete response rates approaching 67% in patients completing neoadjuvant EV-Pembro, a majority of cystectomies are now removing cancer-free bladders. This creates an ethical and clinical imperative to rapidly launch prospective trials to validate bladder preservation strategies and avoid overtreatment.